Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$2M+122%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's change in fair value of contingent consideration?
Supernus Pharmaceuticals (SUPN) reported change in fair value of contingent consideration of $2.39M in Q1 2026.
How has Supernus Pharmaceuticals's change in fair value of contingent consideration changed year-over-year?
Supernus Pharmaceuticals's change in fair value of contingent consideration decreased by 68.8% year-over-year, from $7.66M to $2.39M.
What is the long-term trend for Supernus Pharmaceuticals's change in fair value of contingent consideration?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's change in fair value of contingent consideration has grown at a 268.0% compound annual growth rate (CAGR), from -$510K to $25.42M.
What does change in fair value of contingent consideration mean?
This represents the non-cash adjustment to the fair value of liabilities related to future payments owed to sellers of acquired businesses, contingent upon achieving specific performance milestones. Fluctuations in this value reflect changes in management's expectations regarding the probability and timing of these milestones. It is a critical indicator of the financial impact of past M&A activity on current earnings.